MR.HARIKIRI-INSIGHTS

[rAAV] 特許 0010468 – rAAV vector精製 – アパタイト・クロマト精製法 (レジメ)- ID13457

Written by

harikiri

in

METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORS United States Patent Application 20190010468 Kind Code:A1

http://www.freepatentsonline.com/y2019/0010468.html

概要

  • PEG添加でCHT (and CHF)のDBCを100倍の増強
  • All rAAV

Claim

1. A method for isolating a population of recombinant adeno-associated virus (rAAV) particles from in-process impurities in a feedstream, comprising the steps of:(a) contacting a feedstream containing the rAAV particles with an apatite chromatography medium in the presence of polyethylene glycol (PEG), wherein the rAAV particles bind to the apatite chromatography medium; and(b) eluting the rAAV particles bound to the apatite chromatography medium with an elution buffer containing less than 3% (w/v) PEG.

2. The method of claim 1 , wherein the apatite chromatography medium is ceramic hydroxy apatite (CHT).

3. The method of claim 1, wherein the apatite chromatography medium is ceramic fluoroapatite (CFT).

4. The method of claim 1, wherein the specific binding of the apatite chroma attooggrraapphhyy mmeeddiiuumm ttoo tthhee xrAAAV particles is between 1014 and 1016 DNase-resistant particles per milliliter (DRP/mL).

5. The method of claim 1 , further comprising a step of binding the rAAV particles in the feedstream eluted from the apatite chromatography medium to an anionic chromatography medium.

6. The method of claim 1 , wherein the feedstream containing the rAAV particles in step (a) is contacted with an apatite chromatography medium in the presence of polyethylene glycol (PEG) and a basic buffer.

7. The method of claim 6, wherein the basic buffer is between pH 7.6 and 10.

8. The method of claim 6, wherein the basic buffer is between pH 8.0 and 10.0. 

9. The method of claim 6, wherein the basic buffer is between pH 9.0 and 10.0.

10. The method of claim 6, wherein the basic buffer comprises borate.

11. The method of claim 1, wherein the PEG has an average molecular weight between about 5,000 (PEG5000) grams per mole and about 15,000 (PEG15000) grams per mole.

12. The method of claim 11 , wherein the PEG has an average molecular weight of about 6,000 (PEG6000) grams per mole.

13. The method of claim 1, wherein the feeds tream containing the rAAV particles in step (a) is contacted with the apatite chromatography medium in the presence of between about 3% (w/v) and about 10% (w/v) PEG.

Claims

1. A method for isolating a population of recombinant adeno-associated virus (rAAV) particles from in-process impurities in a feedstream, comprising the steps of: (a) (i) contacting a feedstream containing the rAAV particles with an apatite chromatography medium in the presence of polyethylene glycol (PEG), wherein the rAAV particles bind to the apatite chromatography medium; and (ii) eluting the rAAV particles bound to the apatite chromatography medium with an elution buffer containing less than 3% (w/v) PEG; and (b) (i) contacting the feedstream eluted from the apatite chromatography medium containing the rAAV particles with a hydrophobic interaction chromatography (HIC) medium in a high salt buffer comprising citrate, wherein the rAAV particles and the in-process impurities bind to the HIC medium; and (ii) eluting the rAAV particles bound to the HIC medium with a medium salt buffer.  

2. The method of claim 1, wherein the apatite chromatography medium is ceramic hydroxyapatite (CHT) or ceramic fluoroapatite.  

3. 3–5. (canceled)  

6. The method of claim 1, wherein the feedstream containing the rAAV particles in step (a)(i) is contacted with an apatite chromatography medium in the presence of polyethylene glycol (PEG) and a basic buffer.  

7. (canceled)  

8. The method of claim 6, wherein the basic buffer is between pH 8.0 and 10.0.  

9. (canceled)  

10. The method of claim 6, wherein the basic buffer comprises borate.  

11. The method of claim 1, wherein the PEG has an average molecular weight between about 5,000 (PEG5000) grams per mole and about 15,000 (PEG15000) grams per mole.  

12. (canceled) 

TABLE 2. Screening of resins for binding of rAAV-1 compared to binding of process contaminants

ResinResin TyperAAV-1Helper VirusHost Cell DNASerum AlbuminSerum Proteins
UnoS pH 5.5Cation Exchange+0−++
UnoS pH 7.0Cation Exchange−−−−−
UnoQ pH 8.5Anion Exchange+++++++++++
UnoQ pH 7.0Anion Exchange++++++++++++
Fractogel EMD SO3Cation Exchange+++−00
CHTApatite+0++++
CFTApatite+0++++
HIC PhenylHydrophobic Exchange−−−00
HIC ButylHydrophobic Exchange+++−00
HIC HexylHydrophobic Exchange+++−00
HIC PPGHydrophobic Exchange−−−00
Source SIon Exchange+00++0
Source QIon Exchange+00++0
TMAEIon Exchange+00++0
IMAC FeCl300−++
Superdex 200Gel Filtrationvoidvoidchasechasechase
HW55Gel Filtrationvoidvoidchasechasechase
HW65Gel Filtrationvoidvoidchasechasechase
HW75Gel Filtrationvoidvoidchasechasechase
Key: (−) = present in flow-through (no binding); + = weakly bound (eluted very early in the gradient); ++ to ++++ = stronger binding (eluted further along the gradient).

TABLE 3. Relative strength of binding of rAAV-1 and BSA to apatite resin at pH = 6.5 or pH = 9.0, with or without 5% (w/v) PEG6000

Binding conditionsBSA5% (w/v) PEG6000
pH = 6.50+++
pH = 6.50 + 5% (w/v) PEG6000++++++
pH = 9.0++
pH = 9.00 + 5% (w/v) PEG6000+++++
Key: + = weak binding;, ++ = medium binding; ++++ = strong 

TABLE4. Glucan clearance in the process

Processing stepGlucan concentration (ng/mL)Total amount per lot (ng) (250 L scale)
Clarification10.42,600,000
TFF1361,541,016
CHT elution1.94,769
Post HIC and SEC0.2662
Final Anion Exchange Eluate0.171

TABLE 5. Screening for AAV1 binding in alternative buffers

Total infectious units of Ad5 in CHT column fractionsFraction
Load ratio6.6 mL13.5 mL33 mL
Load9.0 × 1081.3 × 109 9.0 × 108
Flowthrough + chase<2.5 × 105<3.6 × 105<6.9 × 105
PO4 Wash2.9 × 1062.7 × 106<2.6 × 106
Washes II & III3.6 × 1062.2 × 106 2.8 × 106
Elution<6.9 × 104<6.9 × 104<3.5 × 105
Log reduction value (LRV)>4.1>4.3>3.4

TABLE 6

疎水担体として一般的によく使われるButylとPhenylを比較してして、各緩衝液組成の下、パススルーさせた時、そのパススルーの回収率の比較をしている。

一般論として、バッファ組成から吸着性が良いと考えられる条件は、以下の通りであるが、その一般論とは少し異なっているように思われる

  • 吸着性は、酸性pHで強くなり、アルカリ性pHで低くなる
  • 吸着性は、塩濃度が高い程強くなる。ただし、塩の分子量に依存しており、分子量が大きいほど強くなる
  • この表の結果では、この経験則に反しているように見える。このような場合、以下の考察が必要であると考える
    • 塩の種類による可溶性の向上/不要化の促進があるかも知れない
  • 考えられる考察
    • アルカリ性と酸性では、酸性の方が可溶的である
Buffer System TestedButyl 650M (% in flow-through)EMD-Phenyl (% in flow-through)
1.1M Sodium Sulfate (pH = 7)0%0%
1M Sodium Citrate (pH = 7)0%0%
1.3M Potassium Phosphate (pH = 7)3%3%
2.9M NaCl, 50 mM Sodium Citrate (pH = 4)0%28%
1M Glycine, 50 mM Sodium Citrate (pH = 4)4%1%
50 mM Potassium Phosphate (pH =4.5)3%NT
50 mM Sodium Citrate (pH 4)4%NT
2.9M NaCl, 50 mM Potassium Phosphate (pH 4.5)17%NT

TABLE 7. Relative binding of rAAV-1 versus model in-process impurities in different HIC buffers

表から言えることは、rAAV-1は、AAV血清型1で作ったVector、Ad5は、遺伝子治療用で最も使用されるadenovirus血清型5。疎水担体(HIC)への結合性は、rAAV-1よりもAd5の方が強い。不純物であるDNAの結合性は弱い。

Buffer SystemrAAV-1Ad5DNA
0.1M sodium sulfate + bis tris buffer, pH = 7.0+++−
0.8M sodium sulfate, bis tris buffer, pH = 7.0+++0
1M sodium citrate, pH = 7.0+++0
2.9M NaCl (50 mM sodium citrate to buffer at pH = 4.0)−−0
Key: “0” = no binding material present in flow-through; “−” = very weak binder; “+” = strong binder; “++” = stronger binder.

関連記事

[特許] FTO調査 – 自らの技術が特許侵害していないか [2021/05/07]

はじめに 医薬品開発においてコマーシャル製造する場合，工業的に製造という制限として特許侵害を考慮しなければなりません． 特許とは，工業的になにがを実施する場合の制限です．その「んなにか」とは，以下のような項目です．一言で…

[特許関連/記事紹介] 新型コロナウイルスに関する特許の概説記事から – ID15052 [2020/05/02]

記事へのリンクのみ 新型コロナウイルスの特許について、現状を踏まえて概説している記事です。特許の学習として実務的に参考になります。 SARS-CoV-2 Coronavirus and patents20 · 02 · …

[rAAV] 特許 0010468 – rAAV vector精製 – アパタイト・クロマト精製法 (レジメ)- ID13457

METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORS United States Patent Application 20190010468 Kin…

[特許] クレーム内容を理解するために文献レビュー —「対象発明の理解を通じたクレーム作成方法の提案、そしてその応用」、パテント (2013),Vol.66, No.13 – / Udemyのオンライン・ビデオ講座 で完結する – ID13101[2020/11/29]

執筆者が開発した特許の請求項を構造化するメソッドにより、請求項は、「要素」、「続税、および「関係」の3つに分類され、それを簡潔にまとめるメソッド。まとめた各要素の説明文を、ほとんどそのまま使用することで、請求項を書き上げていくメソッド。特許の明細書を作成或いは読む初学者には、大きな第一歩になる、是非、このメソッドを知ってほしい。
Page: 1 2 … 4

関連記事:

AEX purification[rAAV-Edu] rAAV9の精製方法 – 特許, 2017 – ID2566 [2023/10/23] [Data Link] rAAV特許 – アパタイト・クロマト精製法 – ID4443 [2019/12/20] [Data Link] rAAV vectorの沈殿法を使った精製方法に関する文献のリンク – ID745 rAAV精製に必要な精製機材　工事中 – ID1165 Profile of chromatography[rAAV] rAAVベクターの精製方法 – Universal Method (2018) – ID2266 [2019/09/18] [rAAV-Edu] POROS CaptureSelect (AAV精製 resin) の性能とAEXによるfull/emptyの分離 – ID2271 [2019/09/18] [rAAV-Lab] AAVの発現・精製から動物試験までの手順をNovagenのAAV精製キット説明書から知る – ID2407 [2019/09/26] AAV[rAAV] AVB SepharoseによるrAAVの精製, 2009 – ID2461 [2019/09/28] [Data Link] AAVベクター関連特許 – ID4163 [2019/12/09] [Bio-Material] Mustang® Q Membrane Units (2004) を使ったアプリケーション (Pall)

More posts